Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Microbial Keratitis (MK) | OBN
Contact lens wearing has been increased globally during recent decades, which is one of the main risk factors for developing microbial keratitis. Microbial keratitis is a severe and dangerous condition that causes cornea inflammation. Potential Complications of Microbial Keratitis It…
FDA Warns of 26 OTC Eye Drops from Several Major Brands|OBN
The FDA has issued a warning not to purchase or use 26 over-the-counter eye drop products due to the potential risk of eye infections that could lead to partial vision loss or blindness. If patients experience signs or symptoms of…
Is Areds 2 Supplement Good for AMD?
AMD stands for age-related macular degeneration and it is an eye disease where your vision is blurred. Using Areds 2 supplement depends on the stage you have the blurry vision either early intermediate or late. Also depending on AMD in…
EVMANN Takes Two Innovative Companies Under its Umbrella
AMSTERDAM, Oct. 5, 2021 /PRNewswire/ — Within framework of global growth strategy implemented in early 2021, VSY Biotechnology GmbH-Germany and Alsanza Medizintechnik und Pharma GmbH-Germany companies which manufacture and sell their innovative products in ophthalmology and orthopedy fields over 90 countries and 6 continents have decided to…
Glaucoma Market to Grow to $3.5 Billion by 2030
According to GlobalData, the glaucoma market across the seven major markets* is predicted to grow steadily from $2.8 billion in 2020 to $3.5 billion in 2030, with a compound annual growth rate (CAGR) of 2%. According to the latest analysis…
Methylsulfonylmethane Eye Drops Contaminated, FDA Warn
The FDA has issued warning to consumers, advising them against purchasing and immediately discontinuing the use of two products: Dr. Berne’s MSM Drops 5% Solution and LightEyez MSM Eye Drops – Eye Repair. The warning is based on the potential…
Oxular’s OXU-001 Receives IND Acceptence
The U.S. Food and Drug Administration has approved Oxular Limited’s investigational new drug application (IND) for suprachoroidal OXU-001 for the treatment of diabetic macular edema (DME). The IND permits the OXEYE Phase 2 trial to proceed, which will assess the…
Alcon and Ivantis Lose Patent Battle to Sight Sciences.
Sight Sciences announced its success in defeating all four patent invalidity challenges that were filed against it by Alcon and Ivantis in the United States Patent and Trademark Office. Patent Infringement Litigation Over Hydrus® Microstent In September 2021, Sight Sciences…
Théa Obtains Sepofarsen and Ultevursen from ProQR
ProQR Therapeutics and Laboratoires Théa have reached an agreement through which ProQR will transfer its advanced ophthalmic assets, sepofarsen and ultevursen, to Théa. Under the terms of the agreement, ProQR will secure an initial payment totaling €12.5 million ($13.7 million).…
Oyster Pharma’s Tyrvaya Is Widely Available to Patients
Oyster Point Pharma announced the expansion of patient access to its nasal spray medication for dry eye disease, Tyrvaya (varenicline solution), and provided an update In an update on Tyrvaya’s US commercial success in the US. According to Oyster Point,…